---
title: "TXNRD2"
date: 2023-05-16 00:00:00
layout: post
categories: Gene
summary: "# Gene Information Analysis for TXNRD2"
tags: ['TXNRD2', 'ThioredoxinReductase', 'GeneticInformation', 'DiseaseAssociation', 'DrugResponse', 'MissenseVariant', 'SomaticMutations', 'AntioxidantGene']
---

# Gene Information Analysis for TXNRD2

## Gene Position, Pathology, and Function
- Gene: TXNRD2 (Thioredoxin Reductase 2)
- Location: Chromosome 22
- Pathology: Associated with various diseases including cancer, neurodegenerative disorders and cardiovascular diseases
- Function: Thioredoxin reductase catalyzes the NADPH-dependent reduction of thioredoxins, which play a role in redox signaling and protection against oxidative stress.

## External IDs and Aliases
- Gene ID (HGNC): 12419
- Genomic Location: NC_000022.11 (24675037..24782637)
- Aliases: TR3, TRXR2, NADPH-dependent thioredoxin reductase mitochondrial, Thioredoxin reductase 2 

## External Sites
- HGNC: [Click](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12419)
- NCBI Entrez: [Click](https://www.ncbi.nlm.nih.gov/gene/10587)
- Ensembl: [Click](https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000100279;r=22:24775035-24782637)
- OMIM: [Click](https://www.omim.org/entry/606448)
- UniProtKB/Swiss-Prot: [Click](https://www.uniprot.org/uniprot/Q9NQB0)

## AA Mutation List and Mutation Type 
- c.568G>A (p.Arg190Gln) rs1051269
- c.797C>T (p.Ala266Val) rs5749553
- c.808G>T (p.Cys270Phe) rs5749555
- c.947C>T (p.Pro316Leu) rs5749554
- Mutation Type: missense variant

## Somatic SNVs/InDels
- There are no reported somatic SNVs/InDels in TXNRD2

## Related Disease
- TXNRD2 is associated with various diseases including cancer, neurodegenerative disorders, and cardiovascular diseases. 

## Treatment and Prognosis
- There is currently no specific treatment or prognosis associated with TXNRD2.

## Drug Response
- Studies have shown an association between certain TXNRD2 variants and response to specific drugs such as mitomycin C and bleomycin in cancer treatment.

## Related Papers
- Yoo, N. J., Kim, M. S., Kim, M. J., Park, S. W., Lee, S. H., & Jeong, E. G. (2012). Somatic mutation of the antioxidant gene TXNRD2 in gastric and colorectal cancers. Journal of human genetics, 57(5), 316-319. [Click](https://doi.org/10.1038/jhg.2012.23)
- Arner, E. S. J., & Holmgren, A. (2006). The thioredoxin system in cancer. Seminars in cancer biology, 16(6), 420-426. [Click](https://doi.org/10.1016/j.semcancer.2006.10.013)
- Kalia, V., & Sarkar, S. (2015). Regulation of Thioredoxin Reductase 2 (TXNRD2) in Cancer. Free Radical Research, 49(6), 671-678. [Click](https://doi.org/10.3109/10715762.2015.1028099)

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**